Literature DB >> 22772336

Contrasting effects of different cannabinoid receptor ligands on mouse ingestive behaviour.

Jonathan Grey1, Phil Terry, Suzanne Higgs.   

Abstract

This study characterized the effects of seven diverse cannabinoid receptor agonists (and one antagonist) on ingestive behaviour in nondeprived adult, male CD1 mice. Microstructural analysis of licking for a range of concentrations of condensed milk (10, 15 and 20%) was carried out following administration of vehicle or: Δ⁹-tetrahydrocannabinol (Δ⁹-THC) at 1, 3 or 6 mg/kg; CP55,940 at 10, 30 or 50 µg/kg; Win 55,212-2 at 0.5, 1 or 3 mg/kg; HU-210 at 0.01, 0.03 or 0.1 mg/kg; methanandamide at 1, 3 or 6 mg/kg; arachidonyl-2'-chloroethylamide at 1, 3 or 6 mg/kg and JWH133 at 1, 3 or 6 mg/kg. The cannabinoid receptor antagonist/inverse agonist rimonabant was also tested at 0.3, 1 or 3 mg/kg. Test sessions comprised three 30 s presentations of the milk concentrations separated by 10 s interpresentation intervals. The nonselective CB1 receptor agonists Δ⁹-THC, CP55,940 and Win 55,212-2 increased the number of licks for condensed milk, primarily by a significant increase in bout number. The potent and nonselective CB1 receptor agonist HU-210 and the selective CB1 receptor agonists methanandamide and arachidonyl-2'-chloroethylamide did not significantly affect licking behaviour but did significantly increase the latency to start licking. The CB1 receptor antagonist rimonabant produced effects that were opposite in direction to those produced by Δ⁹-THC, CP55,940 and Win 55,212-2. Finally, the selective CB2 receptor agonist JWH133 had no significant effects on behaviour. These data add to reports that cannabinoid agonists can enhance the appetitive aspects of feeding, but they also demonstrate that not all CB1 receptor agonists do this, and therefore the relationship between action at CB1 receptors and appetitive feeding effects is not straightforward.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22772336     DOI: 10.1097/FBP.0b013e328356c3dc

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  5 in total

1.  Characterization of structurally novel G protein biased CB1 agonists: Implications for drug development.

Authors:  Benjamin M Ford; Lirit N Franks; Sherrica Tai; William E Fantegrossi; Edward L Stahl; Michael D Berquist; Christian V Cabanlong; Catheryn D Wilson; Narsimha R Penthala; Peter A Crooks; Paul L Prather
Journal:  Pharmacol Res       Date:  2017-08-23       Impact factor: 7.658

Review 2.  Characterizing ingestive behavior through licking microstructure: Underlying neurobiology and its use in the study of obesity in animal models.

Authors:  Alexander W Johnson
Journal:  Int J Dev Neurosci       Date:  2017-07-03       Impact factor: 2.457

3.  Midbrain response to milkshake correlates with ad libitum milkshake intake in the absence of hunger.

Authors:  Sarah Nolan-Poupart; Maria G Veldhuizen; Paul Geha; Dana M Small
Journal:  Appetite       Date:  2012-10-12       Impact factor: 3.868

Review 4.  Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.

Authors:  Marisol S Castaneto; David A Gorelick; Nathalie A Desrosiers; Rebecca L Hartman; Sandrine Pirard; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2014-08-18       Impact factor: 4.492

5.  Adolescent Exposure to the Synthetic Cannabinoid WIN 55212-2 Modifies Cocaine Withdrawal Symptoms in Adult Mice.

Authors:  María A Aguilar; Juan Carlos Ledesma; Marta Rodríguez-Arias; Carles Penalva; Carmen Manzanedo; José Miñarro; M Carmen Arenas
Journal:  Int J Mol Sci       Date:  2017-06-21       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.